Drugs / BPX-701
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02743611 | Apr 2017 → Jul 2019 | acute myeloid leukemia, myelodysplastic syndrome, uveal melanoma | Bellicum Pharmaceuticals | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BPX-701 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02743611 ↗ |
| Modality | Cell therapy | “genetically modified autologous T cell product” NCT02743611 ↗ |
| Route | Intravenous | “will receive an intravenous infusion of BPX-701” NCT02743611 ↗ |
| Target | PRAME | “Participants' T cells are modified to recognize and target the PRAME tumor marker on cancer cells.” NCT02743611 ↗ |